Gastrointestinal Cancer

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

The phase 2 Actuate 1801 part 3b trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.

Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.

Results from the phase 2/3 trial also show a favorable OS trend for KN026 with chemotherapy vs placebo with chemotherapy in HER2-positive gastric cancer.

Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.

The recommendation from the CHMP is based on results from the phase 2b HERIZON-BTC-01 trial of zanidatamab in advanced HER2+ biliary tract cancer.

According to comparative single-cell transcriptome analyses, NOTCH1 deficiency facilitated a more immunologically active microenvironment in ESCC tumors.

SBRT demonstrated positive 3-year outcomes as a treatment in patients with early-stage HCC based on results from the phase 2 STRSPH trial.

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.

Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.

Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.

Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.

Robot-assisted minimally invasive esophagectomies with anastomotic technique were completed without complications or mortality in a majority of patients.

Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.

Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.

Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.

Postoperative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.

A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.